Entering text into the input field will update the search result below

GlycoMimetics' (GLYC) CEO Rachel King on Q4 2017 Results - Earnings Call Transcript

Mar. 06, 2018 12:22 PM ETGlycoMimetics, Inc. (GLYC)
SA Transcripts profile picture
SA Transcripts

GlycoMimetics (NASDAQ:GLYC) Q4 2017 Results Earnings Conference Call March 6, 2018 8:30 AM ET


Shari Annes - Investor Relations

Brian Hahn - Chief Financial Officer

Rachel King - Chief Executive Officer

Helen Thackray - Senior Vice-President, Clinical Development and Chief Medical Officer


Yatin Suneja - SunTrust Robinson Humphrey

Jotin Marango - Roth Capital

Stephen Willey - Stifel

Biren Amin - Jefferies

Ritu Baral - Cowen


Good morning and thank you all for joining GlycoMimetics call. At this time, all participants are in a listen-only mode. Following management's remarks, we will hold a brief question-and-answer session and at that time, the lines will be opened for you. [Operator Instructions]

I would now like to turn the call over to Shari Annes of the Investor Relations Group at GlycoMimetics. Please go ahead.

Shari Annes

Good morning. Today we will cover not only GlycoMimetics' fourth quarter and year-end financial results, but importantly update you on our Phase 3 development plans for GMI-1271 in AML. Press releases from both yesterday and today are available in the news section of the company's website at www.glycomimetics.com. This call is being recorded. Dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available in the Investor Relations section of the company's website for 30 days.

Joining me on the call today from GlycoMimetics is Rachel King, Chief Executive Officer; Brian Hahn, Chief Financial Officer; and Dr. Helen Thackray, Senior VP of Development and Chief Medical Officer.

We will start today's call with high level comments from Rachel regarding the company's strategic progress, highlighting the overall development program for GMI-1271 in AML. After that, Helen will provide more detail on the planned GlycoMimetics sponsored Phase 3 trial of GMI-1271 in relapsed refractory AML. She will also discuss our

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About GLYC

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on GLYC

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.